Pfizer Breast Cancer Drug Gets FDA's 'Breakthrough' Status
Pfizer Inc. announced Wednesday that its experimental breast cancer treatment palbociclib had been granted "breakthrough therapy" status by the U.S. Food and Drug Administration under a recently implemented program for promising...To view the full article, register now.
Already a subscriber? Click here to view full article